الفهرس 
Renal DevelopmentOnly 14 pages are availabe for public view
 |  | from | 16 |  |  |
| | | from | 16 | | |
Abstract
Adult renal epithelial neoplasms (RENs) comprise several distinct clinicopathologic entities with potential prognostic and therapeutic differences. Both benign and malignant tumors occur in the kidney. The most common malignant tumors in adult is renal cell carcinoma. Tumor growth depends on two main factors, cell proliferation and cell death by apoptosis. The evasion of apoptosis or programmed cell death is a hallmark of carcinogenesis. FAS (CD95,APO-1) is one of the best known members of the death receptor family which can either mediate apoptosis or activate tumor-promoting pathways. The BCL-2 (B-cell lymphoma/leukemia-2) family of both pro- and antiapoptotic proteins are central regulators of apoptosis. BCL-2 is frequently up regulated in RCCs. The aim of this work was to study the expression of both the apoptotic regulator FAS (CD95,APO-1) and antiapoptotic proteins BCL-2. We analysed their expression by immunohistochemistry (IHC) in order to characterize the alteration of the expression of these molecules in the studied neoplasms and their role in tumor progression, grade and the histopathologic types and to differentiate between chromophobe renal cell carcinoma, renal oncocytoma and eosinophilic variant of clear cell RCC.